Amylyx Pharmaceuticals Inc (AMLX)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
AMLX
Amylyx Pharmaceuticals Inc
$16.28
-6.92%
HEALTHCARE · Cap: $1.69B
TAK
Takeda Pharmaceutical Co Ltd ADR
$15.47
+0.97%
HEALTHCARE · Cap: $49.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates -677551989% more annual revenue ($4.51T vs $-665,000). AMLX leads profitability with a 0.0% profit margin vs -3.4%. TAK earns a higher WallStSmart Score of 57/100 (C).
AMLX
Avoid31
out of 100
Grade: F
TAK
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
The strongest argument for AMLX centers on Debt/Equity, Altman Z-Score.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : AMLX
The primary concerns for AMLX are EPS Growth, Market Cap, Profit Margin.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
AMLX profiles as a value stock while TAK is a turnaround play — different risk/reward profiles.
TAK carries more volatility with a beta of 0.09 — expect wider price swings.
TAK is growing revenue faster at 3.9% — sustainability is the question.
AMLX generates stronger free cash flow (-37M), providing more financial flexibility.
Bottom Line
TAK scores higher overall (57/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is a pioneering biopharmaceutical company dedicated to creating transformative therapies for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company’s lead product candidate, AMX0035, features an innovative neuroprotective mechanism that has demonstrated promising results in enhancing patient outcomes. Backed by a strong clinical pipeline and a team of specialists in neurology, Amylyx is strategically positioned to address critical unmet medical needs, presenting a compelling investment opportunity for institutional investors interested in cutting-edge solutions for challenging neurological disorders.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?